.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The landscape of genetic research is evolving rapidly with the introduction of BEstimate. This CRISPR base editing tool addresses a critical gap in current methodologies by offering comprehensive functional annotation of target sequences. Since genomic medicine relies heavily on interpreting variants of uncertain significance, this pipeline provides a robust solution for researchers. It systematically specifies target sites while generating accurate activity and off-target predictions. Consequently, clinicians can better understand the structural and clinical implications of installed variants.
Precision medicine requires highly specific tools to correct disease-causing mutations. BEstimate supports custom guide RNA (gRNA) design against variant alleles, facilitating the programmed reversion of pathogenic variants. Therefore, it is an essential resource for analyzing large-scale base editor screens. Furthermore, the pipeline integrates with clinical databases to provide real-time annotations. This capability ensures that researchers identify the most relevant genetic modifications for potential therapeutic interventions.
The versatility of this tool allows it to handle complex datasets with ease. For instance, it can be used in oncology to model specific cancer-associated mutations. Additionally, hematologists can utilize it to design experiments for correcting single-nucleotide polymorphisms in blood disorders. Because the tool is freely available, it democratizes access to high-end computational genomics. Ultimately, BEstimate empowers scientists to bridge the gap between genetic data and clinical outcomes.
Unlike traditional tools, BEstimate provides a comprehensive pipeline that includes functional, structural, and clinical annotations of the variants being installed.
Yes, the tool supports the reversion of disease variants and custom gRNA design, making it highly valuable for modeling and potentially treating genetic conditions.
Indeed, BEstimate is designed to analyze base editor libraries and screens, making it suitable for high-throughput functional genomics research.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Dinçer C et al. BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments. Genome Biol. 2026 Apr 27. doi: 10.1186/s13059-026-04077-z. PMID: 42045938.
2. Dincer C, et al. BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments. bioRxiv. 2025.
3. CD Genomics. Variant Analysis: Annotation, Interpretation, and Clinical Integration. 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
BEstimate is a flexible computational pipeline for designing base editor gRNA libraries and providing clinical annotations for variants of unknown significa...
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
